In the last 12 months, SNG has received research grants from Pfizer and NIH. FMD and SBT have no conflicts of interest to disclose.
The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis
Article first published online: 29 OCT 2010
© 2010 John Wiley and Sons A/S
Volume 12, Issue 7, pages 702–706, November 2010
How to Cite
Daray, F. M., Thommi, S. B. and Ghaemi, S. N. (2010), The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disorders, 12: 702–706. doi: 10.1111/j.1399-5618.2010.00864.x
- Issue published online: 29 OCT 2010
- Article first published online: 29 OCT 2010
- Received 26 January 2010, revised and accepted for publication 31 July 2010
- antidepressant-induced mania;
- bipolar disorder;
- serotonin transporter gene
Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord 2010: 12: 702–706. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.
Objective: Antidepressant-induced mania (AIM) has been associated with the serotonin-transporter-linked promoter region (5-HTTLPR) polymorphism in some studies but not in others. We conducted a meta-analysis of those studies and other studies of genetic predictors of AIM.
Methods: MEDLINE-based searches of genetic studies of AIM were conducted, and a meta-analysis of six studies of 5-HTTLPR was performed. Other polymorphisms were insufficiently studied to allow for meta-analysis.
Results: There was an association of the short (s) variant of 5-HTTLPR and AIM [risk ratio (RR) = 1.35, 95% confidence interval (CI): 1.04–1.76, p = 0.02]. There was a higher frequency of s carriers (sl and ss genotypes) in those who developed AIM [RR = 1.38, 95% CI: 0.98–1.93), p = 0.06].
Conclusion: The 5-HTTLPR polymorphism appears to have a moderate effect size association with AIM in patients with bipolar disorder.